Who are Epoetin alfa vials's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epogen, continuation (darbepoetinum), ARM A : IV iron + epoietin zeta, Vifor and EPO, human recombinant erythropoietin, rHuEPO.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epoetin-alfa-vials.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Epoetin alfa vials — Competitive Intelligence Brief

Epoetin alfa vials (Epoetin alfa vials) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology/Oncology.

phase 3 Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epoetin alfa vials (Epoetin alfa vials) — GlaxoSmithKline. Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epoetin alfa vials TARGET	Epoetin alfa vials	GlaxoSmithKline	phase 3	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
Epogen	Epoetin Alfa-Epbx	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor	1989-01-01
continuation (darbepoetinum)	continuation (darbepoetinum)	Anemia Working Group Romania	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
ARM A : IV iron + epoietin zeta	ARM A : IV iron + epoietin zeta	Centre Francois Baclesse	marketed	Iron supplement + Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
human recombinant erythropoietin	human recombinant erythropoietin	Seoul National University Bundang Hospital	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)
rHuEPO	rHuEPO	Amgen	marketed	Erythropoiesis-stimulating agent (ESA)	Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

Amgen · 4 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
Hospital de Clinicas de Porto Alegre · 2 drugs in this class
Pfizer · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 2 drugs in this class
Barts & The London NHS Trust · 1 drug in this class
Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epoetin alfa vials — Competitive Intelligence Brief. https://druglandscape.com/ci/epoetin-alfa-vials. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab